Form 4: SOPHiA GENETICS Officer Sells Shares

SOPHiA GENETICS SA Chief Medical Officer, Philippe Menu, reported transactions involving the sale of ordinary shares to cover tax obligations.

Summary

• Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, reported the sale of 2,800 ordinary shares on April 8, 2026, for a weighted average price of $4.837.
• An additional 1,931 ordinary shares were sold on April 9, 2026, at a weighted average price of $4.7393.
• These sales were conducted under a Rule 10b5-1 trading plan to satisfy tax withholding obligations related to vested restricted stock units.
• Following these transactions, Mr. Menu beneficially owns 276,721 ordinary shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider selling, although the explanation of tax withholding and a Rule 10b5-1 plan mitigates significant concern.

Positives

• The sales were executed under a pre-established Rule 10b5-1 trading plan, indicating adherence to compliance and governance standards.
• The transactions were specifically to cover tax withholding obligations, suggesting a routine event rather than a discretionary sale due to company performance concerns.

Negatives

• A total of 4,731 shares were sold by a key executive, which could be perceived negatively by the market, despite the stated reason.
• The weighted average sale prices indicate a slight downward trend in the share price during the reporting period.

Risks

• Potential negative market perception of insider selling, even if for tax purposes.
• The weighted average sale prices suggest a potential decline in share value during the transaction period.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which primarily reports past transactions.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions. While any insider selling can be a point of concern for investors, the explicit mention of a Rule 10b5-1 plan for tax withholding purposes suggests this is a pre-planned, non-discretionary event, common in the biotechnology and healthcare sectors where executive compensation often includes equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: May perceive insider selling negatively, though the explanation of tax withholding and a Rule 10b5-1 plan should temper concerns.
• Management: Demonstrates adherence to compliance procedures for managing equity compensation and associated tax liabilities.

Next Steps

• Monitor future Form 4 filings for any additional transactions by Philippe Menu or other insiders.
• Observe the company's stock performance in light of this transaction and broader market conditions.

Key Dates

Recommendation

The filing reports routine insider share sales for tax purposes under a pre-arranged plan, which is standard practice and does not indicate a negative view of the company's prospects by the executive. While insider selling can be a minor concern, the context provided suggests it's not a signal of distress. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of the company.

Keywords

SOPHiA GENETICS SA, Form 4, Insider Trading, Share Sale, Rule 10b5-1, Tax Withholding, Philippe Menu, Chief Medical Officer, Ordinary Shares